PTC Inc. (PTC)
PTC Inc. (PTC) Discusses Unlocking Business Value and Growth Opportunities in Modern ALM Prepared Remarks Transcript
PTC Inc. (PTC) Discusses Unlocking Business Value and Growth Opportunities in Modern ALM Prepared Remarks Transcript
PTC Targets ALM Growth as Codebeamer Gains Traction in Software-Defined Products
PTC NASDAQ: PTC used a partner webinar to outline what executives described as a significant growth opportunity in application lifecycle management, or ALM, driven by increasingly software-defined products, regulatory demands and the need for large enterprises to modernize engineering processes.
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider's direct common stock holdings.
Reasons Why Investors Should Consider Betting on PTC Stock Now
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
PTC: An Undervalued Digital Moat In Industrial Software
PTC Inc.'s software suite, specifically Creo for computer-aided design (CAD) and Windchill for product lifecycle management (PLM), serves as the foundational architecture for physical R&D workflows. This structural lock-in is verified by a massive 27% year-over-year increase in Remaining Performance Obligations (RPO). A highly secure 95% of total revenue is entirely recurring in nature.
Is the Options Market Predicting a Spike in PTC Stock?
Investors need to pay close attention to PTC stock based on the movements in the options market lately.
Orbit Makes PTC's Recent Pullback Interesting Despite Execution Risks
PTC Inc. still has a steady and recurring lifecycle software base with offerings across CAD, PLM, ALM, SLM, and general SaaS workflows. Their newer offerings, like Orbit and Jetstream, also move PTC towards a clearer AI integration path for its products and services. I do believe the sale of Kepware and ThingWorx changed its prospects a bit. In part, it streamlined PTC's business and helped finance stock buybacks.
Why Is PTC Inc. (PTC) Down 6% Since Last Earnings Report?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
PTC Inc. (PTC) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript
PTC Inc. (PTC) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage
PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk.
PTC Therapeutics Q1 Earnings Call Highlights
PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.
PTC Q2 Earnings & Revenues Beat on AI-Led ARR Strength, Shares Jump
PTC jumped in pre-market trading after fiscal Q2 2026 revenue rose 22% and AI-driven product demand fueled stronger ARR growth and buybacks.
